(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) results for EYLEA HD (aflibercept) Injection 8 mg in patients with wet age-related macular degeneration ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

Bayer has submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the ...

Here are seven more notes: 1. USPI’s net operating revenues for the fourth quarter of 2024 reached $1.3 billion, a 16.9% increase from $1.1 billion in Q4 2023. Growth was driven by higher net revenue ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Eylea, the market leader. The TALON trial ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR trial investigating EYLEA HD (aflibercept) Injection 8 mg. The QUASAR trial ...

QUASAR trial showed EYLEA HD achieved non-inferior visual acuity gains with extended 8-week dosing intervals in macular edema secondary to retinal vein occlusion. PULSAR trial extension demonstrated ...

Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the ...

OpenAI’s board of directors has formally rejected an offer from a group of investors led by Elon Musk to buy the nonprofit for $97.4 billion. Scarlet Fu reports on “Bloomberg The Close.” ...